Line-M Kid Tablet DT is a pediatric formulation combining Levocetirizine (2.5 mg) and Montelukast (4 mg) designed to provide effective relief from allergic conditions in children. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, mitigating bronchoconstriction, inflammation, and mucus production commonly observed in asthma and allergic rhinitis. The combination in Line-M Kid Tablet DT offers a dual mechanism of action, addressing both histamine-mediated and leukotriene-mediated pathways, enhancing symptom control and improving quality of life in pediatric patients with allergic respiratory diseases. The tablet is designed for easy administration, with rapid disintegration suitable for children who have difficulty swallowing conventional tablets. Line-M Kid Tablet DT is indicated for the treatment of allergic rhinitis, chronic urticaria, and as an adjunct in asthma management in children. It should be used under medical supervision, with dosage adjusted according to age and clinical response. Adverse effects are generally mild and may include headache, somnolence, or gastrointestinal discomfort. Caution is advised in patients with hepatic or renal impairment.